FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220785375> ?p ?o ?g. }

• W4220785375 endingPage "313" @default.
• W4220785375 startingPage "308" @default.
• W4220785375 abstract "Prior studies have focused on the clinical efficacy of combination therapy, donepezil and memantine, for patient's diagnosed with Alzheimer's disease. As a result, it has become increasingly routine for providers to prescribe both medications for all-cause neurodegenerative disorders in variable stages of disease. However, the potential adverse drug reactions while described as mild can have serious sequelae in older adults who are already managing the side effects of polypharmacy. This study looks to explore the tolerability of switching cholinesterase inhibitors to memantine monotherapy versus adding memantine as combination therapy for all-cause neurodegenerative disorders.The study is an IRB approved retrospective chart review that includes 175 patients diagnosed with neurocognitive disorders (ICD 10 F00-F03.91 and ICD10 G30-G31.84). Only side effects reported to and recorded by a neurocognitive subspecialist at Jefferson's Memory Disorder Center from 2016 to 2019 were included.The odds of a patient reporting side effects on combination therapy in comparison with those patients on memantine monotherapy reporting side effects were significantly greater (OR = 4.33, CI 95% (1.62, 11.52), p = 0.003). In our patient sample, more than 80% of the patients reporting side effects qualified as polypharmacy or excessive polypharmacy (Table 2). As a result, variable polypharmacy (p = 0.047) was statistically significant in the in a binary logistic regression model for predicting outcomes for patients on combination therapy (Table 3). Therefore, as a patient progresses to moderate-severe stages of disease, we recommend switching CI monotherapy to memantine monotherapy as opposed to adding memantine as combination therapy for those patients on more than 10 other medications to increase tolerability. Given the limitations of a smaller sample size, variables such as severity of disease, renal and liver impairment as well as medication dosing were not significant predictors (Table 3) for those reporting side effects on combination therapy." @default.
• W4220785375 created "2022-04-03" @default.
• W4220785375 creator A5004620817 @default.
• W4220785375 creator A5028543992 @default.
• W4220785375 creator A5030226306 @default.
• W4220785375 creator A5073251954 @default.
• W4220785375 creator A5089576120 @default.
• W4220785375 creator A5008205656 @default.
• W4220785375 date "2022-06-01" @default.
• W4220785375 modified "2023-10-11" @default.
• W4220785375 title "Tolerability of memantine monotherapy versus adding memantine as combination therapy" @default.
• W4220785375 cites W2132806643 @default.
• W4220785375 cites W2225022024 @default.
• W4220785375 cites W2790083419 @default.
• W4220785375 cites W2790440679 @default.
• W4220785375 cites W2907817008 @default.
• W4220785375 cites W3143999600 @default.
• W4220785375 doi "https://doi.org/10.1016/j.jnma.2022.02.006" @default.
• W4220785375 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35272847" @default.
• W4220785375 hasPublicationYear "2022" @default.
• W4220785375 type Work @default.
• W4220785375 citedByCount "1" @default.
• W4220785375 crossrefType "journal-article" @default.
• W4220785375 hasAuthorship W4220785375A5004620817 @default.
• W4220785375 hasAuthorship W4220785375A5008205656 @default.
• W4220785375 hasAuthorship W4220785375A5028543992 @default.
• W4220785375 hasAuthorship W4220785375A5030226306 @default.
• W4220785375 hasAuthorship W4220785375A5073251954 @default.
• W4220785375 hasAuthorship W4220785375A5089576120 @default.
• W4220785375 hasConcept C126322002 @default.
• W4220785375 hasConcept C197934379 @default.
• W4220785375 hasConcept C2776999253 @default.
• W4220785375 hasConcept C2778375690 @default.
• W4220785375 hasConcept C2779134260 @default.
• W4220785375 hasConcept C2779483572 @default.
• W4220785375 hasConcept C2779484449 @default.
• W4220785375 hasConcept C2780904820 @default.
• W4220785375 hasConcept C36434225 @default.
• W4220785375 hasConcept C71924100 @default.
• W4220785375 hasConceptScore W4220785375C126322002 @default.
• W4220785375 hasConceptScore W4220785375C197934379 @default.
• W4220785375 hasConceptScore W4220785375C2776999253 @default.
• W4220785375 hasConceptScore W4220785375C2778375690 @default.
• W4220785375 hasConceptScore W4220785375C2779134260 @default.
• W4220785375 hasConceptScore W4220785375C2779483572 @default.
• W4220785375 hasConceptScore W4220785375C2779484449 @default.
• W4220785375 hasConceptScore W4220785375C2780904820 @default.
• W4220785375 hasConceptScore W4220785375C36434225 @default.
• W4220785375 hasConceptScore W4220785375C71924100 @default.
• W4220785375 hasIssue "3" @default.
• W4220785375 hasLocation W42207853751 @default.
• W4220785375 hasLocation W42207853752 @default.
• W4220785375 hasOpenAccess W4220785375 @default.
• W4220785375 hasPrimaryLocation W42207853751 @default.
• W4220785375 hasRelatedWork W2007674862 @default.
• W4220785375 hasRelatedWork W2028459909 @default.
• W4220785375 hasRelatedWork W2134043280 @default.
• W4220785375 hasRelatedWork W2191112769 @default.
• W4220785375 hasRelatedWork W2256865142 @default.
• W4220785375 hasRelatedWork W2338678376 @default.
• W4220785375 hasRelatedWork W2373211733 @default.
• W4220785375 hasRelatedWork W3022493689 @default.
• W4220785375 hasRelatedWork W4220785375 @default.
• W4220785375 hasRelatedWork W61648805 @default.
• W4220785375 hasVolume "114" @default.
• W4220785375 isParatext "false" @default.
• W4220785375 isRetracted "false" @default.
• W4220785375 workType "article" @default.